Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases
This study is currently recruiting patients.
Sponsored by: | M.D. Anderson Cancer Center |
---|---|
Information provided by: | National Cancer Institute (NCI) |
Purpose
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Strontium-89 may relieve bone pain caused by prostate cancer. Celecoxib may stop the growth of cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. Combining doxorubicin and strontium-89 with celecoxib may kill more tumor cells.
PURPOSE: Randomized phase II trial to compare the effectiveness of doxorubicin and strontium-89 with or without celecoxib in treating patients who have progressive androgen-independent prostate cancer and bone metastases.
Condition | Treatment or Intervention | Phase |
---|---|---|
recurrent prostate cancer stage IV prostate cancer bone metastases |
Drug: celecoxib Drug: doxorubicin Drug: strontium chloride Sr 89 Procedure: chemotherapy Procedure: drug modulation Procedure: isotope therapy Procedure: radiation therapy |
Phase II |
MedlinePlus related topics: Bone Cancer; Cancer; Cancer Alternative Therapy; Prostate Cancer
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Randomized Study of Doxorubicin and Strontium Chloride Sr 89 With or Without Celecoxib in Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases
OBJECTIVES:
OUTLINE: This is a randomized study. Patients are stratified according to extent of bone metastases on bone scan (> 20 lesions vs ≤ 20 lesions) and quality of response (i.e., decline of the prostate-specific antigen from baseline) to prior induction chemotherapy (≥ 80% vs < 80%). Patients are randomized to 1 of 2 treatment arms.
PROJECTED ACCRUAL: A total of 70 patients (35 per treatment arm) will be accrued for this study within 18 months.
Eligibility
Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS: Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY: Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Location and Contact Information
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |